News | Atrial Fibrillation | May 24, 2018

Atrial Fibrillation Patients Diagnosed With Carotid Artery Disease Face Increased Risk of Dementia

Researchers stress importance of handling treatable conditions like AFib and CAD to prevent or postpone dementia

Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

May 24, 2018 — Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.

Blockages in the carotid artery, which gradually build up as people age, restrict blood flow to the brain. The new study shows that a combination of the two diseases and the resulting impact on blood flow significantly increases a patient’s chances of developing dementia.

Prior research has shown the abnormal heart rhythms of atrial fibrillation (Afib) produce inconsistent blood flow to the brain, which contributes to the onset of dementia or a decrease in cognitive function. Risk factors are similar for atrial fibrillation and carotid artery disease and include age, weight, hypertension, high cholesterol and diabetes. Smoking can also increase risk.

“Our team of researchers has been studying links between atrial fibrillation and dementia. This new data stresses the continued need for physicians to monitor and screen patients for both carotid artery disease and atrial fibrillation, especially patients who have risk factors of either disease," said Victoria Jacobs, Ph.D., a clinical researcher with the Intermountain Medical Center Heart Institute.

Results of the study were presented during the Heart Rhythm Society’s 39th annual Scientific Sessions, May 9-12 in Boston.

More than 200,000 new patients are diagnosed each year with carotid artery disease, which is caused by plaque building up in the artery that leads from the brain to the heart. However, the disease is usually asymptomatic until the patient has a stroke.  The largest age group of people affected are those over 60.

Atrial fibrillation, the most common heart arrhythmia in the world, affects more than 2.7 million American adults. The abnormal heart rhythm causes blood to pool and clot in the heart, and when those blood clots break free, they can cause a stroke.

Researchers examined 6,786 patients with carotid artery disease with no history of dementia, and compared those in the group diagnosed with atrial fibrillation to those with no diagnosis of atrial fibrillation.

The average age of the patients was 71.6 years old and 55.6 percent of them were male. Twenty one percent of them had atrial fibrillation.

How can study results help providers and patients reduce the onset of dementia? Jacobs said early awareness and recognition are key.

“Atrial fibrillation and carotid artery disease are treatable, and addressing those diseases early on can help reduce the risk of developing dementia,” said Jacobs. “Physicians should be discussing the treatment options with patients who are at risk to help educate them about what they can do to live the healthiest life possible. Patients should be engaged in their own healthcare, knowledgeable about their risks and active in maintaining healthy lifestyles. Neither disease should be accepted passively, because both are treatable, and treatment is especially important given the benefit of helping to prevent or postpone dementia.”

Researchers will continue to analyze the data to compare it among different groups to see what patterns may exist in identifying a patient’s risk of developing dementia.

Members of the research team include: Kevin G. Graves, MHI; Heidi T. May, Ph.D.; Victoria Jacobs, Ph.D.; Tami L. Bair; Brian G. Crandall, M.D.; Michael J. Cutler, DO, Ph.D.; Charles Mallender, M.D.; Jeffrey S. Osborn, M.D.; Peter Weiss, M.D.; John D. Day, M.D.; and Jared Bunch, M.D.

For more information: www.intermountainhealthcare.org

Read other news from the Heart Rhythm Society 2018 Scientific Sessions

Related Content

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking